AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

Emphasis must be on balancing enforcement with innovation, protection with access, and litigation with alternative dispute resolution ...

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to beat back the virus and prevent new infections.

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

Fortunately, this year’s Special 301 Report flags compulsory licensing in Colombia, restrictive patent standards in Argentina and India, and opaque pricing and reimbursement practices in Japan ...

Quality information is even more important now in an age of AI slop where the information ecosystem is awash in misleading images and strange blah words that sound like they mean something but don’t ...

Merging the Crown use and compulsory licensing regimes by introducing a single, streamlined framework for public interest access to patented technologies. Allow both government and private entities to ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...